Oncolytic Viruses As Therapeutic Tools for Pediatric Brain Tumors

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2018 Jul 11

PMID 29987215

Citations 18

Authors

Maider Varela-Guruceaga

Sonia Tejada-Solis

Marc Garcia-Moure

Juan Fueyo

Candelaria Gomez-Manzano

Ana Patino-Garcia

Marta M Alonso

Affiliations

Soon will be listed here.

Abstract

In recent years, we have seen an important progress in our comprehension of the molecular basis of pediatric brain tumors (PBTs). However, they still represent the main cause of death by disease in children. Due to the poor prognosis of some types of PBTs and the long-term adverse effects associated with the traditional treatments, oncolytic viruses (OVs) have emerged as an interesting therapeutic option since they displayed safety and high tolerability in pre-clinical and clinical levels. In this review, we summarize the OVs evaluated in different types of PBTs, mostly in pre-clinical studies, and we discuss the possible future direction of research in this field. In this sense, one important aspect of OVs antitumoral effect is the stimulation of an immune response against the tumor which is necessary for a complete response in preclinical immunocompetent models and in the clinic. The role of the immune system in the response of OVs needs to be evaluated in PBTs and represents an experimental challenge due to the limited immunocompetent models of these diseases available for pre-clinical research.

Citing Articles

The heterogeneous sensitivity of pediatric brain tumors to different oncolytic viruses is predicted by unique gene expression profiles.

Vazaios K, Stavrakaki E, Vogelezang L, Ju J, Waranecki P, Metselaar D Mol Ther Oncol. 2024; 32(2):200804.

PMID: 38694569 PMC: 11060958. DOI: 10.1016/j.omton.2024.200804.

Evolving Diagnostic and Treatment Strategies for Pediatric CNS Tumors: The Impact of Lipid Metabolism.

Fernandez-Garcia P, Malet-Engra G, Torres M, Hanson D, Rossello C, Roman R Biomedicines. 2023; 11(5).

PMID: 37239036 PMC: 10216525. DOI: 10.3390/biomedicines11051365.

Therapeutic Options in Neuro-Oncology.

Afonso M, Brito M Int J Mol Sci. 2022; 23(10).

PMID: 35628161 PMC: 9140894. DOI: 10.3390/ijms23105351.

New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of Pediatric Medulloblastoma.

Fang F, Rosenblum J, Ho W, Heiss J Cancers (Basel). 2022; 14(9).

PMID: 35565414 PMC: 9100249. DOI: 10.3390/cancers14092285.

The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma.

Ghasemi D, Fleischhack G, Milde T, Pajtler K Cancers (Basel). 2022; 14(3).

PMID: 35158947 PMC: 8833659. DOI: 10.3390/cancers14030679.

References

Ostrom Q, de Blank P, Kruchko C, Petersen C, Liao P, Finlay J . Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011. Neuro Oncol. 2014; 16 Suppl 10:x1-x36. PMC: 4277295. DOI: 10.1093/neuonc/nou327. View

Stolarek R, Gomez-Manzano C, Jiang H, Suttle G, Lemoine M, Fueyo J . Robust infectivity and replication of Delta-24 adenovirus induce cell death in human medulloblastoma. Cancer Gene Ther. 2004; 11(11):713-20. DOI: 10.1038/sj.cgt.7700731. View

Alemany R, Balague C, Curiel D . Replicative adenoviruses for cancer therapy. Nat Biotechnol. 2000; 18(7):723-7. DOI: 10.1038/77283. View

Chan W, Rahman M, McFadden G . Oncolytic myxoma virus: the path to clinic. Vaccine. 2013; 31(39):4252-8. PMC: 3755036. DOI: 10.1016/j.vaccine.2013.05.056. View

Barber G . VSV-tumor selective replication and protein translation. Oncogene. 2005; 24(52):7710-9. DOI: 10.1038/sj.onc.1209042. View

Adamson P . Improving the outcome for children with cancer: Development of targeted new agents. CA Cancer J Clin. 2015; 65(3):212-20. PMC: 4629487. DOI: 10.3322/caac.21273. View

Moss B . Reflections on the early development of poxvirus vectors. Vaccine. 2013; 31(39):4220-2. PMC: 3755097. DOI: 10.1016/j.vaccine.2013.03.042. View

Adelfinger M, Gentschev I, de Guibert J, Weibel S, Langbein-Laugwitz J, Hartl B . Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-5b451 for feline mammary carcinoma therapy. PLoS One. 2014; 9(8):e104337. PMC: 4122492. DOI: 10.1371/journal.pone.0104337. View

Kaufman H, Kohlhapp F, Zloza A . Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015; 14(9):642-62. PMC: 7097180. DOI: 10.1038/nrd4663. View

10.

Ajina A, Maher J . Prospects for combined use of oncolytic viruses and CAR T-cells. J Immunother Cancer. 2017; 5(1):90. PMC: 5696728. DOI: 10.1186/s40425-017-0294-6. View

11.

Miyachi M, Imafuku S . Incidence of serum antibody titers against herpes simplex virus in Japanese patients. J Dermatol. 2016; 44(1):47-51. DOI: 10.1111/1346-8138.13506. View

12.

Liu Z, Zhao X, Mao H, Baxter P, Huang Y, Yu L . Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma. Neuro Oncol. 2013; 15(9):1173-85. PMC: 3748915. DOI: 10.1093/neuonc/not065. View

13.

Friedman G, Langford C, Coleman J, Cassady K, Parker J, Markert J . Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111. J Neurooncol. 2009; 95(2):199-209. PMC: 4574288. DOI: 10.1007/s11060-009-9926-0. View

14.

Jones D, Kieran M, Bouffet E, Alexandrescu S, Bandopadhayay P, Bornhorst M . Pediatric low-grade gliomas: next biologically driven steps. Neuro Oncol. 2017; 20(2):160-173. PMC: 5786244. DOI: 10.1093/neuonc/nox141. View

15.

Skowron P, Ramaswamy V, Taylor M . Genetic and molecular alterations across medulloblastoma subgroups. J Mol Med (Berl). 2015; 93(10):1075-84. PMC: 4599700. DOI: 10.1007/s00109-015-1333-8. View

16.

Studebaker A, Kreofsky C, Pierson C, Russell S, Galanis E, Raffel C . Treatment of medulloblastoma with a modified measles virus. Neuro Oncol. 2010; 12(10):1034-42. PMC: 3018921. DOI: 10.1093/neuonc/noq057. View

17.

Lun X, Zhou H, Alain T, Sun B, Wang L, Barrett J . Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res. 2007; 67(18):8818-27. PMC: 4380180. DOI: 10.1158/0008-5472.CAN-07-1214. View

18.

Ribi K, Relly C, Landolt M, Alber F, Boltshauser E, Grotzer M . Outcome of medulloblastoma in children: long-term complications and quality of life. Neuropediatrics. 2006; 36(6):357-65. DOI: 10.1055/s-2005-872880. View

19.

Lun X, Ruan Y, Jayanthan A, Liu D, Singh A, Trippett T . Double-deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors. Mol Oncol. 2013; 7(5):944-54. PMC: 5528451. DOI: 10.1016/j.molonc.2013.05.004. View

20.

Niemann J, Kuhnel F . Oncolytic viruses: adenoviruses. Virus Genes. 2017; 53(5):700-706. DOI: 10.1007/s11262-017-1488-1. View